Theratechnologies Inc. TH.TO
Set alert
As of Sep 26, 3:45 PM ET
- Open
- 4.47
- Prev close
- 4.47
- Mkt cap
- 118.63M
- Vol
- 35.47K
- Avg vol
- 49.20K
- EPS
- -0.06
- P/E
- -17.19
- Div yield
- 0.00%
More statistics
- Low
- 4.36
- High
- 4.53
- Forward P/E
- 16.13
- Beta
- 1.73
- Short ratio
- 0.10
- Inst. own
- 51.56%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.86
- 200-d avg
- 1.82
- 1y target
- 8.00
Key statistics
- Market cap
- 118.63M
- Enterprise value
- 133.93M
- Trailing P/E
- 0.00
- Forward P/E
- 16.13
- PEG ratio
- 0.00
- Price / sales
- 1.41
- Price / book
- 0.00
- EPS (TTM)
- -0.06
- Beta
- 1.73
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -3.74%
- Revenue (TTM)
- 84.32M
- Revenue growth
- 8.40%
- Free cash flow
- -6.60M
- Total cash
- 38.86M
- Total debt
- 57.83M
- Return on equity
- 0.00%
- Shares outstanding
- 45.98M
- Short % of float
- 0.01%
- 50-day average
- 1.86
- 200-day average
- 1.82
Analyst view
Consensus: buy
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.069.
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- theratech.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on TH.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Arena (Joseph) | Director of Issuer | Acquisition or disposition in the public market | Oct 20, 2022 | 15,000 |
| Holler (Frank A) | Director of Issuer | Acquisition or disposition in the public market | May 2, 2022 | 39,000 |
| Lafond (Jocelyn) | Senior Officer of Issuer | Acquisition or disposition in the public market | Jul 20, 2022 | 21,000 |
| Svoronos (Dawn A) | Director of Issuer | Exercise of options | Oct 19, 2022 | 323,600 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Soleus Capital Management, L.P. | 10.44% | 4,801,376 | 12.39M | Sep 29, 2024 |
| AIGH Capital Management LLC | 8.10% | 3,725,204 | 9.61M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 5.83% | 2,682,228 | 6.92M | Sep 29, 2024 |
| Morgan Stanley | 4.90% | 2,253,894 | 5.82M | Sep 29, 2024 |
| National Bank of Canada/FI | 0.41% | 186,815 | 481.98K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.32% | 145,254 | 374.75K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 25,681 | 66.26K | Oct 30, 2024 |